Datum Orthopedics

Datum Orthopedics was founded to provide innovative orthobiologic and orthopedic bone formation, ossification, and tissue regeneration solutions.
We develop advanced biomaterials designed to improve long term healing and regeneration of musculoskeletal components.

The unique ossification properties of Datum’s GLYMATRIX® based products make them ideal new entrants for spine fusion and fracture grafts in trauma. Datum Orthopedics will concentrate its initial efforts on bone graft products.

Products featuring Datum Biotech’s patented GLYMATRIX® technology have been used safely and effectively in over half a million dental and aesthetic procedures, with over 110 scientific publications and numerous case studies.

Datum Orthopedics is currently in a round of fund-raising.
Please contact us regarding current investment opportunities or for company information.

Gilad Karni | CEO

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Phasellus eget orci nec lorem pellentesque ultricies. Curabitur eu odio libero. Etiam lacus dolor, malesuada vel accumsan bibendum, tempus id turpis. Vivamus massa enim, ornare dignissim placerat eu, maximus at leo. Donec vitae porta urna. Vivamus rutrum cursus velit, nec posuere sem faucibus laoreet. Mauris sit amet lacinia felis. Quisque lobortis massa imperdiet facilisis fermentum. Aenean id enim vel elit ornare auctor ut vel sem. Suspendisse dignissim quis neque ac finibus. Aliquam eget ligula neque. Integer tempus, dolor id posuere cursus, urna nisl maximus nisl, id dapibus purus dolor sed leo. Nunc maximus gravida porta. Quisque elementum ex eu porta accumsan. Cras purus orci, pellentesque nec aliquam non, hendrerit non nibh. Sed odio arcu, maximus id elementum vel, sagittis in mi.tech

 

Itay Itzhaky | Chairman

Mr. Itay Itzhaky has over 30 years of managerial and entrepreneurial experience in the pharmaceutical and healthcare industries in Israel.

Prior to Datum Biotech, and co-founding Datum Dental, Mr. Itzhaky served as CEO of NiTi Surgical Solutions during 2007-2012, leading the company in development of Nitinol-based disruptive medical devices. Prior to NiTi, Mr. Itzhaky was CEO of ColBar, a biomaterials company (acquired by Johnson & Johnson). Before Colbar, Itay spent 7 years at Teva Pharmaceutical Industries in senior operational positions, managing generic and innovative drug-development operations. Itay was VP Business Development at Promedico, the largest drug importer in Israel (representing Novartis, Pfizer, Abbott etc.). In this capacity, he founded and managed start-up subsidiaries in the medical device and pharmaceutical fields. Prior to these positions, Mr. Itzhaky served as CEO of Eldan Electronic instruments, representing medical device and life science companies such as Hewlett-Packard (Agilent), Amersham Pharmacia Biotech etc.

Mr. Itzhaky holds a B.Sc. in Industrial Engineering from Ben-Gurion University of the Negev, Beer-Sheba, Israel and an MBA from Bar Ilan University, Ramat Gan, Israel.

Arie Goldlust PhD | R&D

Dr. Arie Goldlust has 30 years of R&D experience in the medical device, biotechnology and pharmaceutical industries. Arie has led the development of a number of worldwide commercialized collagen based products. He has also developed a range of novel tissue engineering scaffolds and led collaborations with different companies and J&J research units in a variety of other biomaterial projects. 

In 2011, Dr. Goldlust co-founded Datum Biotech and the following year co-founded Datum Dental. Prior to co-founding Datum Biotech, Dr. Goldlust served for 10 years at ColBar LifeScience, a J&J subsidiary. 

Prior to joining Colbar, Arie was Manager of Process Development and Protein Research at CBD Technologies, Ltd. and before that, held a research position at the Department of Process Development of Biotechnology General.

Dr. Goldlust received his Ph.D and M.Sc. degrees in biochemistry from the Weizmann Institute of Science, Rehovot, Israel and his B.Sc. degree from the Hebrew University of Jerusalem.. He completed his post‐doctoral training at the Department of Biological Chemistry, University of Michigan Medical School, Ann Arbor, Michigan USA and at the Department of Biotechnology, Parke‐Davis Pharmaceutical‐Research Division of Warner‐Lambert Company, Ann Arbor, Michigan USA.

Arie Goldlust PhD

Click

Yafit Keret - CFO

Ms. Yafit Keret has over 16 years of experience in the business and financial management of hi-tech and clean-tech companies. 

Her expertise includes both financial operation of parent companies as well as establishment and management of subsidiaries located abroad. Yafit has extensive knowledge in founding companies, exit procedures, fundraising, and business development. Her work includes daily financial management which consists of, but is not limited to, auditing, preparation of financial reports, issues concerning tax aspects, as well as active participation in board meetings.

Ms. Keret holds an MBA, Business & Finance and BA and CPA certification, Accounting and Business.

Contact us

[recaptcha]

© All rights reserved Datum Orthopedics Ltd. Israel, 2018-2019

Cell +972-52-3115931 (Gilad Karni, CEO) | Gilad.k@datumortho.com| Follow us on Linkedin